No quarterly revenue total was found in Q/C Technologies, Inc.'s SEC filings.
Q/C Technologies, Inc. (QCLS) files with the SEC under industry code 2835, In Vitro & In Vivo Diagnostic Substances. As of Jun 30, 2026 it held $11.0 million in cash and investments and $371,171 in total debt.
Revenue
—
Net income
$-6.62M
-268.3% vs year-ago quarter
Operating cash flow
$-1.82M
+12.0% vs year-ago quarter
Free cash flow
—
EPS
$-0.79
+98.5% vs year-ago quarter
Dividend per share
None
Shares outstanding
8.19M
-95.4% vs year-ago quarter
Net cash
$10.62M
Q2 FY2026
Operating margin
-439.3%
TTM
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- QCLS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1321834
- Former names
- Q/C TECHNOLOGIES, INC. (until Oct 2, 2026); TNF Pharmaceuticals, Inc. (until Sep 10, 2025); MyMD Pharmaceuticals, Inc. (until Jul 1, 2024); Akers Biosciences, Inc. (until Apr 16, 2021); Akers Biosciences Inc (until Apr 11, 2017)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$6.8M | -$1.9M | -$3.7M | -$1.8M | -$1.9M |
| Net income | -$6.6M | -$1.2M | -$5.9M | -$2.8M | -$1.8M |
| Diluted EPS | -$0.79 | -$0.19 | -$1.27 | -$2.50 | -$51.10 |
| Operating cash flow | -$1.8M | -$3.3M | -$3.2M | -$1.2M | -$2.1M |
| Total assets | $22.9M | $38.3M | $41.2M | $37.2M | $17.2M |
| Total liabilities | $3.8M | $14.6M | $16.4M | $15.9M | $5.6M |
| Stockholders' equity | $16.1M | $20.7M | $21.8M | $14.3M | $5.3M |
| Cash and investments | $11.0M | $13.0M | $15.8M | $3.1M | $3.6M |
| Total debt | $371,171 | — | — | $0 | $0 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Officer or director change, Regulation FD disclosure
|
Sep 18, 2026 | Sep 14, 2026 |
| 8-K |
Current report
Agreement ended, Officer or director change
|
Sep 11, 2026 | Sep 10, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Agreement ended, Other events
|
Jul 2, 2026 | Jun 26, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 10-K/A | Amended annual report | Apr 29, 2026 | Dec 31, 2025 |
All 604 Q/C Technologies, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.